The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Rinvoq (upadacitinib) on 2025-10-10. This regulatory action pertains to an efficacy supplement, indicating an expansion or modification of the drug's approved uses based on new data demonstrating its effectiveness. The supplemental application, identified as NDA211675 S-28, was submitted by AbbVie, the drug's sponsor.
Background
Upadacitinib, marketed under the brand name Rinvoq, is a therapeutic agent developed by AbbVie. Supplemental applications for efficacy, such as this one, are typically filed when new clinical data supports an expanded indication, a new patient population, or an improved efficacy claim for an already approved drug. This process allows for the continuous updating of a drug's label to reflect the latest scientific evidence regarding its effectiveness.
What this means
This supplemental approval for Rinvoq (upadacitinib) signifies that the FDA has reviewed and accepted new evidence supporting an additional or enhanced efficacy claim for the drug. For clinicians, this means that upadacitinib is now officially recognized for an expanded therapeutic application, which could involve a new disease state, a different patient demographic, or a refined treatment paradigm within an existing indication. Patient advocates and researchers will find this update relevant as it broadens the scope of available treatments and informs future research directions for conditions where upadacitinib may now be indicated. The specific details of the expanded efficacy will be crucial for understanding the full impact of this regulatory decision on clinical practice and patient care, offering new options for managing relevant health conditions.
Source
The information regarding this supplemental approval for Rinvoq (upadacitinib) was obtained from the official U.S. Food and Drug Administration (FDA) database. The approval, identified as supplemental application NDA211675 S-28, was recorded on 2025-10-10. This public record is accessible via accessdata.fda.gov, specifically within the Center for Drug Evaluation and Research (CDER) section, which provides comprehensive regulatory information on approved drugs and their associated applications. This source serves as the primary reference for the FDA's decision on this efficacy supplement.